Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Non-Hodgkin's Lymphoma
Interventions: DRUG: Mesna|DRUG: Saline|DRUG: Doxorubicin|DRUG: Cyclophosphamide
Sponsor: Mara Chambers